Timeline

Voting rights breakdown

Declared beneficial owners · 8

A single, collectively filed disclosure: the voting-rights rate applies to the whole group, not to each person.

• Corey Goodman77.37%
• Kurt von Emster77.37%
• Paul Brooke77.37%
• Robert Adelman77.37%
• Amgen Inc77.37%
• Abingworth LLP77.37%
• Aisling Capital Partners III, LLC77.37%
• Joseph Anderson77.37%

Notice details

Beneficial owner

Corey Goodman

Sale of shares by a member of the group - Warrants, convertible loan notes and options are directly held by venBio Global Strategic Fund L.P., which is controlled by venBio Global Strategic GP L.P., c/o Walkers Corporate Services Limited, Walker House, 87 Mary Street, George Town, Grand Cayman KYI-9005, Cayman Islands, as general partner. venBio Global Strategic GP L.P, in turn, is controlled by venBio Global Strategic GP Ltd., c/o Walkers Corporate Services Limited, Walker House, 87 Mary Street, George Town, Grand Cayman KYI-9005, Cayman Islands, as general partner. venBio Global Strategic GP Ltd. is jointly controlled by Corey Goodman, Marshall, USA, Kurt von Emster, Belmont, USA, Paul Brooke, New York, USA, and Robert Adelman, Hillsborough, USA. Kurt von Emster and Paul Brooke also hold certain employee options on shares in the Company directly. - Shares in the Company, warrants and convertible loan notes are directly held by Amgen Investments Ltd., which is owned 100% by Amgen Manufacturing Ltd., Canon's Court, 22 Victoria Street, Hamilton HM 12, Bermuda. Amgen Manufacturing Ltd. is owned 100% by Amgen Technology Ltd., Canon's Court, 22 Victoria Street, Hamilton HM 12, Bermuda, which is owned 10% by Amgen International Inc., 2711 Centerville Road, Suite 400, Wilmington, DE 19808, USA, and 90% by Amgen Inc., a public company listed on the NASDAQ. Amgen Inc. owns 100% of Amgen International Inc. - Warrants and convertible loan notes are directly held by Abingworth Bioventures V L.P., which is controlled by Abingworth Bioventures V GP L.P., 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ, as general partner. Abingworth Bioventures V GP L.P, in turn, is controlled by Abingworth Bioventures V GP Limited, 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ, as general partner. Abingworth Bioventures V GP Limited, in turn, is controlled by Abingworth LLP. Certain employee options on shares in the Company are held for the account of Abingworth LLP as the investment manager of Abingworth Bioventures V L.P., by Joseph Anderson, Surrey, UK. - Warrants are directly held by Abingworth Bioequities Master Fund Limited, which operates as an integrated investment structure. Abingworth Bioequities Master Fund Limited is fed by (i) Abingworth Bioequities Fund Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands, and by (ii) Abingworth Bioequities Fund L.P., 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801, USA. Abingworth Bioequities Fund Limited is managed by Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN, UK. Abingworth Bioequities Fund L.P is controlled by Abingworth Bioequities GP Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands, as general partner. Abingworth Bioequities GP Limited, in turn, is controlled by Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN, UK. - Warrants and convertible loan notes are directly held by Aisling Capital III, LP, 888 Seventh Avenue, New York, NY 10106, USA, whose general partner is Aisling Capital Partners III, LP, 888 Seventh Avenue, New York, NY 10106, USA. The general partner of Aisling Capital Partners III, LP, 888 Seventh Avenue, New York, NY 10106, USA, is Aisling Capital Partners III, LLC, 888 Seventh Avenue, New York, NY 10106, USA. Aisling Investors III, LP, 888 Seventh Avenue, New York, NY 10106, USA, is an affiliated limited partner. Aisling Capital, LLC, 888 Seventh Avenue, New York, NY 10106, USA, is the investment manager.